{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T02:24:00Z","timestamp":1785723840503,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["XDB1060000"],"award-info":[{"award-number":["XDB1060000"]}],"id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273767"],"award-info":[{"award-number":["82273767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173832"],"award-info":[{"award-number":["82173832"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173653"],"award-info":[{"award-number":["82173653"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFA1210200"],"award-info":[{"award-number":["2024YFA1210200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118675","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:39:39Z","timestamp":1770943179000},"page":"118675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, synthesis and pharmacological evaluation of new SMARCA2 degraders bearing a furo[3,2-c]pyridazine scaffold"],"prefix":"10.1016","volume":"308","author":[{"given":"Jiaming","family":"Diao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaodong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghua","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3865-5908","authenticated-orcid":false,"given":"Zilan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118675_bib1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41556-018-0258-1","article-title":"Chromatin regulatory mechanisms and therapeutic opportunities in cancer","volume":"21","author":"Valencia","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.118675_bib2","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500447","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics","volume":"1","author":"Kadoch","year":"2015","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118675_bib3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.tips.2025.07.008","article-title":"Swinging the SWI\/SNF complexes for cancer therapy","volume":"46","author":"Jing","year":"2025","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.118675_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of Mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.118675_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055119","article-title":"The spectrum of SWI\/SNF mutations, ubiquitous in human cancers","volume":"8","author":"Shain","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118675_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117319","article-title":"SMARCA2 protein: structure, function and perspectives of drug design","volume":"286","author":"Guo","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng.2922","article-title":"Recurrent SMARCA4 mutations in small cell carcinoma of the ovary","volume":"46","author":"Jelinic","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.118675_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059772","article-title":"BRG1 is a prognostic marker and potential therapeutic target in human breast cancer","volume":"8","author":"Bai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118675_bib9","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2017.12.013","article-title":"BRG1 is correlated with poor prognosis in colorectal cancer","volume":"73","author":"Pyo","year":"2018","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2026.118675_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2025.152499","article-title":"Clinical and pathological characteristics and prognostic factors of SMARCA4-deficient non-small cell lung cancer","volume":"78","author":"Zhang","year":"2025","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.ejmech.2026.118675_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.118675_bib12","doi-asserted-by":"crossref","first-page":"5551","DOI":"10.1038\/s41467-020-19402-8","article-title":"Functional characterization of SMARCA4 variants identified by targeted exome-sequencing of 131,668 cancer patients","volume":"11","author":"Fernando","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118675_bib13","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/ng.2928","article-title":"Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4","volume":"46","author":"Ramos","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2026.118675_bib14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118675_bib15","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1073\/pnas.1316793111","article-title":"Functional epigenetics approach identifies BRM\/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers","volume":"111","author":"Hoffman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.118675_bib16","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1158\/0008-5472.CAN-12-4593","article-title":"A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1","volume":"73","author":"Oike","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118675_bib17","doi-asserted-by":"crossref","first-page":"10155","DOI":"10.1021\/acs.jmedchem.8b01318","article-title":"Discovery of orally active inhibitors of Brahma Homolog (BRM)\/SMARCA2 ATPase activity for the treatment of Brahma Related Gene 1 (BRG1)\/SMARCA4-Mutant cancers","volume":"61","author":"Papillon","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib18","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1021\/acs.jmedchem.4c02535","article-title":"Discovery of FHD-286, a first-in-class, orally bioavailable, allosteric dual inhibitor of the Brahma Homologue (BRM) and Brahma-Related Gene 1 (BRG1) ATPase activity for the treatment of SWItch\/Sucrose Non-Fermentable (SWI\/SNF) dependent cancers","volume":"68","author":"Vaswani","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib19","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/0008-5472.CAN-14-3798","article-title":"The SMARCA2\/4 ATPase domain surpasses the bromodomain as a drug target in SWI\/SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies","volume":"75","author":"Vangamudi","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118675_bib20","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1021\/acs.jmedchem.4c01904","article-title":"Discovery of SMD-3236: a potent, highly selective and efficacious SMARCA2 degrader for the treatment of SMARC4-deficient human cancers","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib21","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118675_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in binding confers selectivity in ligand-induced protein degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118675_bib23","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41589-019-0294-6","article-title":"BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design","volume":"15","author":"Farnaby","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.118675_bib24","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118675_bib25","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118675_bib26","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1038\/s41467-022-34562-5","article-title":"Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers","volume":"13","author":"Cantley","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.118675_bib27","doi-asserted-by":"crossref","first-page":"10761","DOI":"10.1021\/acs.jmedchem.3c00953","article-title":"Discovery of SMD-3040 as a potent and selective SMARCA2 PROTAC degrader with strong in vivo antitumor activity","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib29","series-title":"Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation","year":"2025"},{"key":"10.1016\/j.ejmech.2026.118675_bib30","unstructured":"B.K. Albrecht, A. Cote, T. Crawford et al., Preparation of Therapeutic Pyridazine Compounds Useful as Inhibitors of BRG1, BRM and PB1, WO2016138114 A1."},{"key":"10.1016\/j.ejmech.2026.118675_bib31","doi-asserted-by":"crossref","first-page":"14680","DOI":"10.1021\/acs.jmedchem.0c01242","article-title":"Pan-SMARCA\/PB1 bromodomain inhibitors and their role in regulating adipogenesis","volume":"63","author":"Wanior","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib32","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1021\/acs.jmedchem.0c01111","article-title":"Discovery of first-in-class protein arginine methyltransferase 5 (PRMT5) degraders","volume":"63","author":"Shen","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib33","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1021\/acs.jmedchem.1c00047","article-title":"Scaffold-Hopping strategy on a series of proteasome inhibitors led to a preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Thomas","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118675_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/acsmedchemlett.9b00350","article-title":"Spiro-oxindole piperidines and 3-(azetidin-3-yl)-1H-benzimidazol-2-ones as mGlu2 receptor PAMs","volume":"11","author":"de Lucas","year":"2020","journal-title":"ACS Med. Chem. Lett."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426001200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T21:10:35Z","timestamp":1779743435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426001200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"alternative-id":["S0223523426001200"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118675","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and pharmacological evaluation of new SMARCA2 degraders bearing a furo[3,2-c]pyridazine scaffold","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118675"}}